Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Routes of Drug Administration: Parenteral01:25

Routes of Drug Administration: Parenteral

The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel approach for the management of infrabony periodontal defects using autologous dentin and L-PRF: a clinical case series report.

Frontiers in oral health·2026
Same author

Effects of undernutrition and hydroxytyrosol supplementation in late pregnancy on cow-calf performance, metabolic and immune status, and newborn vitality in beef herds.

Animal : an international journal of animal bioscience·2026
Same author

Outcomes in allogeneic hematopoietic stem cell transplantation for Fanconi anemia.

Bone marrow transplantation·2025
Same author

Exploratory analysis of local extreme-temperature attributable mortality in an urban city of Madrid.

Social science & medicine (1982)·2023
Same author

Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.

Blood cancer journal·2022
Same author

A negative energy balance during the peri-implantational period reduces dam IGF-1 but does not alter progesterone or pregnancy-specific protein B (PSPB) or fertility in suckled cows.

Domestic animal endocrinology·2020

Related Experiment Video

Updated: Jul 14, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

[Intravenous immunoglobulin: another therapeutic application].

R de Gracia1, C Jiménez, F Gil

  • 1Departamento de Nefrología, Hospital Universitario La Paz, Madrid, España. raqueldegracia@yahoo.es

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|June 15, 2007
PubMed
Summary

Intravenous immunoglobulin (IVIG) can serve as a long-term maintenance immunosuppressor in renal transplant patients unable to take oral medications. This approach, used for three months, demonstrated efficacy without adverse effects.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Experiment Videos

Last Updated: Jul 14, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Intravenous immunoglobulin (IVIG) possesses immunomodulatory properties.
  • IVIG is typically used short-term in renal transplantation, often adjunctively, primarily for refractory rejection.
  • Its role as a primary, long-term maintenance immunosuppressor in renal transplant recipients is not established.

Observation:

  • A renal transplant patient required prolonged intravenous therapy due to inability to tolerate oral intake for three months.
  • This patient received IVIG as the principal immunosuppressive agent, alongside low-dose intravenous methylprednisolone.

Findings:

  • The study reports the first instance of IVIG being utilized as a long-term (three months) maintenance immunosuppressive treatment in a renal transplant recipient.
  • This prolonged IVIG administration was achieved without any discernible secondary effects.

Implications:

  • This case suggests that IVIG may be a viable and safe alternative for long-term maintenance immunosuppression in specific renal transplant patient populations.
  • Further research is warranted to explore the broader applicability and long-term outcomes of IVIG as a primary immunosuppressive strategy in transplantation.